Understanding the molecular role of syndecan-1 in the regulation of caspase-6 during the progression of cardiac arrhythmia

被引:0
|
作者
Wu, Yuanchu [1 ]
Chen, Lin [1 ]
Wang, Caihong [1 ]
机构
[1] Nantong Univ, Affiliated Wujiang Hosp, Dept Cardiol, 2666 Ludang Rd, Suzhou 215200, Jiangsu, Peoples R China
关键词
cardiac arrhythmia; caspase-6; syndecan-1; C57BL; KS-lepr(db); lepr(db); ATRIAL-FIBRILLATION; CARDIOMYOPATHY; PREVALENCE; ACTIVATION; FIBROSIS; DISEASE; MODEL; MICE; TAU;
D O I
10.3892/etm.2021.10614
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The role of caspase-6 in heart disease is not well understood, particularly with respect to cardiac arrhythmia. Also, the function of syndecan-1 in the stimulation of inflammation or a regenerative response after cardiac injury is unclear. Leptin receptor-deficient (C57BL/KS-lepr(db)/lepr(db)) mice were used in the present study. In addition to developing type 2 diabetes, they also develop initial- and end-stage cardiac arrhythmia after 5 and 8 months, respectively. The initial and end-stage arrhythmias were confirmed through progressive variations in the PP intervals observable in electrocardiograms. Histopathological images of the cardiac tissue exhibited scattered and loosened cardiac cells at the initial stage of cardiac arrhythmia, whereas tissue hardness and extensive structural changes in cardiomyocytes were evident at the end stage. At the molecular level, the progressive upregulation of caspase-6 was observed as the cardiac arrhythmia progressed. In the initial stage of arrhythmia, immunohistochemistry revealed that caspase-6 was expressed at the surface of cardiac cells, suggesting that caspase-6 targeted the extracellular matrix, leading to a loosening of the cardiac tissue structure. In the end stage of cardiac arrhythmia, caspase-6 expression was abundant in the cytoplasm, as well as at the cell surface, suggesting that caspase-6 may have cleaved intermediate filaments, paving the way for cellular morphological changes and apoptosis. Notably, syndecan-1 was upregulated 5.8-fold in the initial stage of cardiac arrhythmia, but downregulated at the end stage. Syndecan-1 may restrict the expression of caspase-6 in the initial stage of cardiac arrhythmia, while its downregulation at the end stage may allow destructive changes via caspase-6 overexpression. Furthermore, the knockdown of syndecan-1 using small interfering RNA enhanced the expression of caspase-6 in the cardiac tissue by factors of 1.8 and 1.2 at the initial and end stages of cardiac arrhythmia, respectively, compared with that in non-silenced cardiac tissue. Therefore, it may be concluded that syndecan-1 plays a major role in the regulation of caspase-6 during the pathological stages of cardiac arrhythmia.
引用
收藏
页数:7
相关论文
共 49 条
  • [1] The role of syndecan-1 during endometrial carcinoma progression
    Solmaz, Ozgen Arslan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (06) : 1265 - 1269
  • [2] The role of actomyosin in the regulation of syndecan-1 in hyperosmosis
    Li, Weiqi
    Wang, Wen
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2021, 1865 (10):
  • [3] Activation and Regulation of Caspase-6 and Its Role in Neurodegenerative Diseases
    Wang, Xiao-Jun
    Cao, Qin
    Zhang, Yan
    Su, Xiao-Dong
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55, 2015, 55 : 553 - 572
  • [4] Midkine and syndecan-1 levels correlate with the progression of malignant gastric cardiac adenocarcinoma
    Hu, Xiu-Feng
    Yao, Jun
    Gao, She-Gan
    Yang, Yan-Tong
    Peng, Xiu-Qing
    Feng, Xiao-Shan
    MOLECULAR MEDICINE REPORTS, 2014, 10 (03) : 1409 - 1415
  • [5] Syndecan-1 adhesion molecule is reduced during malignant progression of oral epithelium
    Soukka, T
    Inki, P
    Happonen, RP
    ORAL ONCOLOGY, VOL V, 1997, : 571 - 574
  • [6] Role of cited-1 and caspase-6 expression in HELLP syndrome
    Ocal, E.
    Akalin, S. Alkan
    Asir, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (07) : 3082 - 3087
  • [7] Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression
    Rangarajan, Sunil
    Richter, Jillian R.
    Richter, Robert P.
    Bandari, Shyam K.
    Tripathi, Kaushlendra
    Vlodavsky, Israel
    Sanderson, Ralph D.
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2020, 68 (12) : 823 - 840
  • [8] Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours
    Mennerich, D
    Vogel, A
    Klaman, I
    Dahl, E
    Lichtner, RB
    Rosenthal, A
    Pohlenz, HD
    Thierauch, KH
    Sommer, A
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (09) : 1373 - 1382
  • [9] Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer
    Martini, Carmela
    Logan, Jessica M.
    Sorvina, Alexandra
    Gordon, Colin
    Beck, Andrew R.
    Ung, Ben S-Y
    Caruso, Maria C.
    Moore, Courtney
    Hocking, Ashleigh
    Johnson, Ian R. D.
    LI, Ka lok
    Karageorgos, Litsa
    Hopkins, Ashley M.
    Esterman, Adrian J.
    Huzzell, Chelsea
    Brooks, Robert D.
    Lazniewska, Joanna
    Hickey, Shane M.
    Bader, Christie
    Parkinson-Lawrence, Emm
    Weigert, Roberto
    Sorich, Michael J.
    Tewari, Prerna
    Martin, Cara
    O'Toole, Sharon
    Bates, Mark
    Ward, Mark
    Mohammed, Bashir
    Keegan, Helen
    Watson, William
    Prendergast, Sophie
    Heffernan, Sheena
    Nimhaolcatha, Sarah
    O'Connor, Roisin
    Malone, Victoria
    Carter, Marguerite
    Ryan, Katie
    Brady, Nathan
    Clarke, Andres
    Sokol, Filip
    Prabhakaran, Sarita
    Stahl, Juergen
    Klebe, Sonja
    Samaratunga, Hemamali
    Delahunt, Brett
    Selemidis, Stavros
    Moretti, Kim L.
    Butler, Lisa M.
    O'Leary, John J.
    Brooks, Douglas A.
    PATHOLOGY, 2023, 55 (01) : 40 - 51
  • [10] A Role for Syndecan-1 and Claudin-2 in Microbial Translocation During HIV-1 Infection
    Smith, Anthony J.
    Schacker, Timothy W.
    Reilly, Cavan S.
    Haase, Ashley T.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (03) : 306 - 315